Serrapeptase Option
Hi Rhonda,
Unfortunately there are no human studies that I have been able to find that used serrapeptase to reduce atherosclerosis. In my opinion, if an article makes a claim such as the one you mentioned and then offers no studies to support the claim, then the claim is merely an opinion.
When you check PubMed and search serrapeptase and atherosclerosis, you get zero results. They don't even have animal studies to support that claim.
When you search AI for the same, this is the answer it gives :
While some animal and in vitro studies have suggested potential benefits of serrapeptase in reducing arterial plaque buildup and inflammation associated with atherosclerosis, human clinical trials with rigorous methodologies are needed to establish its effectiveness and safety in treating or preventing atherosclerosis. '
This is the reason that I chose Nattokinase instead of Lumbrokinase or Serrapeptase, because Nattokinase not only had one human study, it had three or more, but there were over 1, 000 participants in the study I discussed to add further credibility to their findings. Overall it was a very good study and my short experience with trying to replicate the study results in myself has already exceeded their results in a shorter period of time than the study length.
I'm sure there is anecdotal evidence to support most of the proteolytic enzymes for atherosclerosis, but I was looking for science based evidence for the article and only nattokinase had that requirement. Given the above, I am sorry to say I have no suggestion for the dosing of serrapeptase for the purpose of reducing atherosclerosis.
Art
(Massachusetts)
08/09/2024
https://brewersciencelibrary.com/prodimages/Basic Cardiovascular Packet ALL.pdf
articles by Dr. Hans A. Nieper, MD
